2. Signaling Pathways
  3. Cytoskeleton
  4. Integrin
  5. Integrin Isoform
  6. Integrin Inhibitor

Integrin Inhibitor

Integrin Inhibitors (68):

Cat. No. Product Name Effect Purity
  • HY-N0416
    Cucurbitacin B
    		Inhibitor 99.91%
    Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity.
  • HY-14571
    E7820
    		Inhibitor 99.25%
    E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity.
  • HY-18644
    CWHM-12
    		Inhibitor 99.77%
    CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
  • HY-163333
    αvβ5 integrin-IN-2
    		Inhibitor
    αvβ5 integrin-IN-2 (Cpd_AV2) is an αvβ5 integrin inhibitor that disrupts the stability of integrin heterodimers. αvβ5 integrin-IN-2 targets the β-propeller central pocket of ITGAV (integrin αV). αvβ5 integrin-IN-2 induces cellular apoptosis.
  • HY-12290
    Arg-Gly-Asp-Ser
    		Inhibitor 99.93%
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
  • HY-100445A
    αvβ1 integrin-IN-1 TFA
    		Inhibitor 98.04%
    αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects.
  • HY-B0686
    Eptifibatide
    		Inhibitor 99.96%
    Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
  • HY-14857
    Carotegrast
    		Inhibitor 98.93%
    Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.
  • HY-18676
    OSU-T315
    		Inhibitor 99.88%
    OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.
  • HY-P0290
    GRGDSP
    		Inhibitor 99.91%
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
  • HY-P9934
    Abciximab
    		Inhibitor 99.966%
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
  • HY-16143
    Cilengitide TFA
    		Inhibitor
    Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
  • HY-47888
    PLN-1474
    		Inhibitor 99.30%
    PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.
  • HY-P0295
    Gly-Arg-Gly-Asp-Ser
    		Inhibitor 99.87%
    Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM
  • HY-70073
    Zaurategrast
    		Inhibitor 98.07%
    Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor.
  • HY-107587
    A-286982
    		Inhibitor 99.33%
    A-286982 is a potent and allosteric LFA-1/ICAM-1 interaction inhibitor with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively.
  • HY-18676B
    ILK-IN-2
    		Inhibitor 99.41%
    ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.
  • HY-N2587
    Irigenin
    		Inhibitor 99.84%
    Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
  • HY-110117
    BIRT 377
    		Inhibitor 98.07%
    BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1), with a Ki of 25.8 nM. BIRT 377 also inhibits the production of IL-2 in vivo. BIRT 377 can be used for researching inflammatory and immune disorders.
  • HY-U00003
    ICAM-1-IN-1
    		Inhibitor 99.94%
    ICAM-1-IN-1 is a potent and selective inhibitor of E-selectin and ICAM-1 with IC50 values of 7 and 5 nM, respectively.